Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Ends AZD9412 IFN-β Asthma Trial For Redesign, Relaunch

Executive Summary

AstraZeneca is stopping a Phase IIa trial assessing in-licensed AZD9412's effect on asthma patients because fewer of them than expected had their condition worsen, making it difficult for the respiratory specialist to gauge the drug's efficiency. AstraZeneca will now re-design the endpoints and resume the study in 2017.

You may also be interested in...



Why AZ Respiratory Head Believes Third-Placed Benralizumab Can Conquer Market

AstraZeneca hopes its investigative biologic benralizumab has strongly differentiated itself from rival therapies Nucala and Cinqair with the detailed publication of Phase III data showing it significantly cut exacerbations and improved lung function and symptoms in patients with severe eosinophilic asthma, as well as offering a favorable dosing schedule.

Synairgen, Pharmaxis Pair Up On LOXL2 Lung Disease Therapy

UK biotechnology company Synairgen plc is teaming up with Australian pharmaceutical company Pharmaxis Ltd to develop a new drug for idiopathic pulmonary fibrosis (IPF) which it hopes to pair up with a big pharma on later down the line.

Job Cuts As Nordic Nanovector Extends Cash Runway

Shrinking cash and COVID-19 uncertainty have prompted Nordic Nanovector to slash costs and focus purely on its lead asset’s pivotal trial in third-line follicular lymphoma.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1123310

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel